Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
A novel series of pyrido[2,3-]pyrimidines; pyrido[3,2-][1,3,4]triazolo; and tetrazolo[1,5-]pyrimidines were synthesized via different chemical transformations starting from pyrazolo[3,4-]pyridin-6-yl)-,-dimethylcarbamimidic chloride (prepared from the reaction of -aminonitrile and phosogen iminiumchloride). The structures of the newly synthesized compounds were elucidated based on spectroscopic data and elemental analyses. Designated compounds are subjected for molecular docking by using Auto Dock Vina software in order to evaluate the antiviral potency for the synthesized compounds against SARS-CoV-2 (2019-nCoV) main protease M . The antiviral activity against SARS-CoV-2 showed that tested compounds , , and had the most promising antiviral activity with lower IC values compared to Lopinavir, "the commonly used protease inhibitor". Both in silico and in vitro results are in agreement.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863666 | PMC |
http://dx.doi.org/10.3390/molecules28020739 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!